- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01159561
Western Equine Encephalitis Vaccine, Inactivated (WEE)
Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Objectives:
Primary: To assess safety of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92.
Secondary: To evaluate immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Fort Deterick, Maryland, United States, 21702-5011
- Clinical Research Unit, Division of Medicine, USAMRIID
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-55 years of age
- In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations
- Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration
- Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody
- WEE, EEE, VEE, and CHIK PRNT80<1:10
- Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form
- Be willing to comply with all follow-up visits, testing, and AE reporting
Exclusion Criteria:
- Participant in the USAMRIID SIP
- Receipt of any other vaccine or investigational; drug within 30 days prior to study entry
- Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination
- Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination
- Hypersensitivity to any vaccine
- Allergic to any vaccine component: Human serum albumin, Neomycin
- Receipt of or anticipates receipt of blood products during the study
- Female: Pregnant or breastfeeding
- Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaccinated
Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
|
Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subjects Reporting Adverse Events by Vaccination and Sex
Time Frame: 28 days following each vaccination
|
28 days following each vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity
Time Frame: Baseline and multiple dates throughout study
|
The primary endpoint used to measure immunogeniciyt of the WEE vaccine, the 80% plaque-reduction neautralization titer (PRNT 80), will be evaluated for subjects in the per protocol population. The secondary endpoint will be GMT, with 95% CI, of the PRNT 80 for WEE-specific antibodies at each scheduled timepoint. |
Baseline and multiple dates throughout study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ronald B Reisler, MD, USAMRIID Medical Division
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Encephalomyelitis
- Alphavirus Infections
- Togaviridae Infections
- Encephalitis
- Encephalomyelitis, Equine
- Encephalomyelitis, Western Equine
Other Study ID Numbers
- A-15812
- USAMRIID FY09-02 (Other Identifier: IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Virus
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
National Institute of Allergy and Infectious Diseases...CompletedHealthy | Epstein Barr Virus InfectionUnited States
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, ChinaRecruiting
-
U.S. Army Medical Research and Development CommandCompleted
-
U.S. Army Medical Research and Development CommandActive, not recruiting
-
Merck Sharp & Dohme LLCCompletedVaricella Virus Infection
-
ModernaTX, Inc.RecruitingRespiratory Syncytial VirusCanada, United Kingdom, Japan, United States, Chile, Denmark, Panama, South Africa
-
Merck Sharp & Dohme LLCCompletedRespiratory Syncytial VirusUnited Kingdom
-
Dalhousie UniversityImmunoVaccine Technologies, Inc. (IMV Inc.)CompletedRespiratory Syncytial VirusCanada
Clinical Trials on Western Equine Encephalitis Vaccine
-
U.S. Army Medical Research and Development CommandUnknownWestern Equine EncephalitisUnited States
-
U.S. Army Medical Research and Development CommandCompletedEastern Equine EncephalitisUnited States
-
Ichor Medical Systems IncorporatedUS Army Medical Research Institute of Infectious DiseasesCompletedVenezuelan Equine Encephalitis Virus InfectionUnited States
-
PharmaJet, Inc.United States Department of DefenseRecruiting
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
NovartisNovartis VaccinesCompletedEncephalitis, Tick-BorneGermany
-
Boryung Pharmaceutical Co., LtdCompletedJapanese EncephalitisKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedJapanese Encephalitis | EncephalitisThailand
-
PfizerCompletedTick-borne EncephalitisAustria, Germany
-
PfizerCompleted